

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	<b>4DS Memory Limited</b>
<b>ABN</b>	43 145 590 110

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	<b>Mr David McAuliffe</b>
<b>Date of last notice</b>	<b>7 May 2019</b>

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct and Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Concept Biotech Pty Ltd (director related entity) David Jeremiah McAuliffe <The Lazy D9M Investment Trust> (trustee and beneficiary) Margaret Elizabeth Livingston (spouse)
<b>Date of change</b>	29 November 2019
<b>No. of securities held prior to change</b>	<b>Direct</b> <u>David McAuliffe</u> 2,521,839 fully paid ordinary shares <b>Indirect</b> <u>Concept Biotech Pty Ltd</u> 2,498,812 fully paid ordinary shares <u>David Jeremiah McAuliffe&lt;D9M Investment Trust&gt;</u> 8,056,743 fully paid ordinary shares <u>Margaret Elizabeth Livingston</u> 7,000,000 unlisted options exercisable at \$0.052 each on or before 22 January 2024, with 1,250,000 subject to vesting conditions
<b>Class</b>	Fully paid ordinary shares
<b>Number acquired</b>	Direct – 245,901
<b>Number disposed</b>	-

## Appendix 3Y

### Change of Director's Interest Notice

<b>Value/Consideration includes brokerage/gst</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Non-cash consideration. Issue of shares in lieu of accrued salary at a deemed issue price of \$0.061 per share as approved by shareholders at the annual general meeting held on 29 November 2019.
<b>No. of securities held after change</b>	<b>Direct</b> <u>David McAuliffe</u> 2,767,740 fully paid ordinary shares <b>Indirect</b> <u>Concept Biotech Pty Ltd</u> 2,498,812 fully paid ordinary shares <u>David Jeremiah McAuliffe&lt;D9M Investment Trust&gt;</u> 8,056,743 fully paid ordinary shares <u>Margaret Elizabeth Livingston</u> 7,000,000 unlisted options exercisable at \$0.052 each on or before 22 January 2024, with 1,250,000 subject to vesting conditions
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Issue of shares in lieu of accrued salary at a deemed issue price of \$0.061 per share as approved by shareholders at the annual general meeting held on 29 November 2019.

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A-
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

## Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.